A Randomized Trial to Compare Topical MJ1 with Routine Care for the Treatment of Cutaneous Leishmaniasis

Mohsen Janghorbani, Masoumeh Faraji, Javad Ramazanpour, Reza Fadaei


The objective of this study was to assess the relative efficacy and tolerability of topical MJ1 compared to routine care in the treatment of histologically proven CL. A total of 150 patients with 297 lesions were randomly allocated to receive either topical MJ1 agent as a paste to applied to the lesions without cover three times a day for 20 days or routine care (intramuscular injection of meglumine antimonate 20 mg/kg/day for 2 weeks or intralesional 0.5-1 cc for a total of four injection with one week interval). The primary end point of this study was the clinical cure of the lesion. Response to treatment was assessed at 1, 2, 3 and 8 weeks after start of therapy. Of the 132 lesions treated with MJ1, the mean size of lesions decreased from 423.9 to 30.4 mm2, 111 (84.1%) were reduced in size and 21 (15.9%) not responded. Correspondingly, in the 165 lesions treated with routine care, the mean size of lesions slightly increased from 295.8 to 330.5 mm2, 82 (49.7%) were reduced in size and 83 (50.3%) not responded. The differences were statistically significant (P<0.001). No sever adverse effect occurred. The findings highlight that topical treatment with MJ1 agent was much more effective than routine care and is safe and well tolerated.


Cutaneous Leishmaniasis, Meglumine Antimonate, MJ1 Agent, Iran

Full Text:



Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27(5):305-18.

Momeni AZ, Reiszadeh MR, Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose MA. Int J Dermatol 2002; 41(7):441-443.

World Health Organization. Control of the leishmaniasis. Report of a meeting of the WHO expert committee on the control of Leishmaniasis, Geneva, 22-26 March 2010, geneva World Health Organization.

Vega-Lopez, Hay RJ. Parasitic worms and protozoa. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook's textbook of Dermatology, 8th edn. Oxford: Blackwell Scirenec, 2010:37.33-37.44.

González U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008; (4):CD005067.

Navin TR, Arana BA, Arana FE, Berman JD, Chajón JF. Placebo-controlled clinical trial of sodium stiboguconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165(1):528-34.

Zerehsaz F, Salmanpour R, Handjani F, Ardehali S, Panjehshahin MR, Tabei SZ, Tabatabaee HR. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimonate for the treatment of cutaneous leishmaniasis in Iran. Int J Dermatol 1999; 38(8):610-612.

Sharquie KA, Najim RA, Farjou IB. A comparative controlled clinical trial of intralesionally administered zinc sulphate, hypertonic sodium chloride and pentavalent animony compound against acute cutaneous leishmaniasis. Clin Exp Dermatol 1997; 22(4):169-73.

El-on J, Jacobs GP, Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 1988; 4(3):76-81.

Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24(4):684–703.

Miller MA, McGowan SE, Gantt KR, Champion M, Novick SL, Andersen KA, Bacchi CJ, Yarlett N, Britigan BE, Wilson ME. Inducible resistance to oxidant stress in the protozoan Leishmania chagasi. J Biol Chem 2000; 275(43):33883–33889.

Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995; 53(6):648–651.

Robledo S, Puerta J, Munoz D, Guardo M, Vélez ID. Eficacia y tolerancia de la pentamidina en el tratamiento de la leishmaniasis cutánea producida por Leishmania (V.) panamensis en Colombia. Biomedica (Bogota) 2006; 26(1):188–193.

Velez I, Agudelo S, Hendricks E, Puerta J, Grogl M, Modabber F, Berman J. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 1997; 126(3):232–236.

Alkhawajah AM, Larbi E, Al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasiswith antimony: intramuscular versus intralesional administration. Ann Trop Med Parasitol 1997; 91(8):899-905.

Firooz A, Khatami A, Khamesipour A, Nassiri-Kashani M, Behnia F, Nilforoushzadeh M, Pazoki-Toroudi H, Dowlati Y. Intralesional injection of 2% zinc sulfate solution in the treatment of acute Old World cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial. J Drug Dermatol 2005; 4(1): 73–79.

Sadeghian G, Nilfroushzadeh A, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Demartol 2007; 32(4): 371–374.

Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43(4): 281–283.

Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harandi A. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 2003; 97(5): 493–498.

Nilforoushzadeh M, Reisszadeh MR, Jafari F. Topical trichloroacetic acid compared with intralesional Glucantime injection in the treatment of acute wet cutaneous leishmaniasis: an open clinical trial. Iran J Dermatol 2003; 6(2): 34–39. [InPersian].

Nassiri Kashani M, Sadr B, Nilforoushzadeh M, Arasteh M, Babakoohi S, Firooz A. Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gun. Int J Dermatol 2010; 49(9): 1034–1037.

Schultz K, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273(5): 408–412.

Janghorbani M, Sadeghinia A, Asilian A, Mohammadzadeh Z. Primary results of topical dairy extract (MJ1) versus intralesionally-administered meglumine anitmonate for treatment of cutaneous leishmaniasis in Isfahan, Iran: a randomized controlled clinical trial. Hamdard Medicus 2003; 46(3): 53-58

Iranian Journal of Health, Safety and Environment e-ISSN: :2345-5535 Iran university of Medical sciences, Tehran, Iran